MedTrace Logo

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

NCT05859477 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-01-02

No results posted yet for this study

Summary

The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in combination with CAPOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative metastatic gastric cancer.

Conditions

  • Metastatic Gastric Cancer
  • PD-L1 Gene Amplification
  • FGFR2 Amplification

Interventions

DRUG

Nivolumab

360 mg, i.v., every 3 weeks

DRUG

Capecitabine

capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle

DRUG

Oxaliplatin

130 mg/m², i.v., day 1, every 3 weeks

Sponsors & Collaborators

  • Kidney Cancer Research Bureau

    lead OTHER

Principal Investigators

  • Ilya Tsimafeyeu · Bureau for Cancer Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-05
Primary Completion
2023-12-01
Completion
2024-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859477 on ClinicalTrials.gov